Billowria Koushal, Das Gupta Ghanshyam, Chawla Pooja A
Department of Pharmaceutical Analysis, ISF College of Pharmacy, Moga-142001, Punjab, India.
Department of Pharmaceutics, ISF College of Pharmacy, Moga-142001, Punjab, India.
Anticancer Agents Med Chem. 2023;23(2):124-141. doi: 10.2174/1871520622666220523145609.
Amivantamab was approved on May 21st, 2021, by United States food and drug administration with the brand name Rybervant, used particularly for adult patients with exon20 insertion of epithelial growth factor receptor with locally advanced metastatic non-small cell lung cancer.
In this review, we explain the non-small cell lung cancer and molecular distinctions between non-small cell lung cancer and small cell lung cancer. We also conclude numerous components of non-small cell lung cancer, which include signs and symptoms of Amivantamab in inhibiting the cancer cell growth, various clinical trials on Amivantamab, adverse effects, and the contraindications of Amivantamab.
A comprehensive literature search was conducted in the relevant databases like ScienceDirect, PubMed, ResearchGate, and Google Scholar to identify studies.
Amivantamab is a new bispecific antibody that targets non-small cell lung cancer through two different pathways, i.e., by binding to epithelial growth factor receptor and mesenchymal epithelial transition factor. Amivantamab gets tightly bound to Fcγ3R, and thus, mediates the macrophage and NK-cell for the killing of cancer cells. Biological treatment of Amivantamab shows effectiveness against the epithelial growth factor receptor Exon20 insertions according to the preclinical data of the animal model.
2021年5月21日，美国食品药品监督管理局批准了amivantamab，商品名为Rybervant，特别用于治疗具有表皮生长因子受体外显子20插入的局部晚期转移性非小细胞肺癌成年患者。
在本综述中，我们解释了非小细胞肺癌以及非小细胞肺癌与小细胞肺癌之间的分子差异。我们还总结了非小细胞肺癌的众多组成部分，包括amivantamab抑制癌细胞生长的体征和症状、关于amivantamab的各种临床试验、不良反应以及amivantamab的禁忌症。
在ScienceDirect、PubMed、ResearchGate和谷歌学术等相关数据库中进行了全面的文献检索以识别研究。
Amivantamab是一种新型双特异性抗体，通过两种不同途径靶向非小细胞肺癌，即通过与表皮生长因子受体和间充质上皮转化因子结合。Amivantamab与Fcγ3R紧密结合，从而介导巨噬细胞和自然杀伤细胞杀伤癌细胞。根据动物模型的临床前数据，amivantamab的生物治疗对表皮生长因子受体外显子20插入显示出有效性。
